SITC 2021 | Assessing the predicative value of the pre-treatment TCR repertoire

Afaf Abed, MBBS, FRACP, Fiona Stanley Hospital, Murdoch, Australia, discusses the implications of using the pre-treatment T-Cell receptor (TCR) repertoire as a predictive and prognostic marker in patients with non-small-cell lung cancer (NSCLC). The pre-treatment TCR repertoire has been effective in predicting progression-free survival (PFS) in patients, but there is no significant association between the pre-treatment TCR repertoire and overall survival (OS), which may be due to a small cohort. Dr Abed additionally highlights the significance of the findings in a clinical and biological context. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.